Compare SURG & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SURG | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 61.1M |
| IPO Year | N/A | 2017 |
| Metric | SURG | RFL |
|---|---|---|
| Price | $0.79 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 166.4K | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $113.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.75 | $1.12 |
| 52 Week High | $3.47 | $3.19 |
| Indicator | SURG | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 71.85 |
| Support Level | $0.75 | $1.41 |
| Resistance Level | $0.95 | $1.64 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 20.96 | 73.17 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.